Literature DB >> 14690409

Modeling tau polymerization in vitro: a review and synthesis.

T Chris Gamblin1, Robert W Berry, Lester I Binder.   

Abstract

The major antigenic component of neurofibrillary pathology in a large number of neurodegenerative diseases consists of the microtubule-associated protein tau. It is currently unclear how tau protein makes the transition from an important component of the microtubule-based cytoskeleton to an insoluble polymerized state. In vitro techniques have been employed to study the polymerization of tau in an effort to understand the underlying molecular mechanisms responsible for this process. These efforts have resulted in the elucidation of roles played by the different parts of the molecule in the polymerization process. Here we discuss the advantages and disadvantages of the various techniques used to model tau polymerization and the discoveries arising from these techniques that have led to a better structural understanding of tau polymerization in relation to Alzheimer's disease and other tauopathies.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14690409     DOI: 10.1021/bi035722s

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  38 in total

1.  Drug discovery for Alzheimer's disease: the end of the beginning.

Authors:  Lorenzo M Refolo; Howard M Fillit
Journal:  J Mol Neurosci       Date:  2004       Impact factor: 3.444

Review 2.  Tau in neurodegenerative diseases: tau phosphorylation and assembly.

Authors:  J Avila; M Pérez; F Lim; A Gómez-Ramos; F Hernández; J J Lucas
Journal:  Neurotox Res       Date:  2004       Impact factor: 3.911

3.  The amino terminus of tau inhibits kinesin-dependent axonal transport: implications for filament toxicity.

Authors:  Nichole E LaPointe; Gerardo Morfini; Gustavo Pigino; Irina N Gaisina; Alan P Kozikowski; Lester I Binder; Scott T Brady
Journal:  J Neurosci Res       Date:  2009-02       Impact factor: 4.164

4.  Combinatorial Tau pseudophosphorylation: markedly different regulatory effects on microtubule assembly and dynamic instability than the sum of the individual parts.

Authors:  Erkan Kiris; Donovan Ventimiglia; Mehmet E Sargin; Michelle R Gaylord; Alphan Altinok; Kenneth Rose; B S Manjunath; Mary Ann Jordan; Leslie Wilson; Stuart C Feinstein
Journal:  J Biol Chem       Date:  2011-02-02       Impact factor: 5.157

5.  Potential neuroprotective strategies against tauopathy.

Authors:  Jeanna M Wheeler; Chris R Guthrie; Brian C Kraemer
Journal:  Biochem Soc Trans       Date:  2012-08       Impact factor: 5.407

6.  TOC1: a valuable tool in assessing disease progression in the rTg4510 mouse model of tauopathy.

Authors:  Sarah M Ward; Diana S Himmelstein; Yan Ren; Yifan Fu; Xiao-Wen Yu; Kaleigh Roberts; Lester I Binder; Naruhiko Sahara
Journal:  Neurobiol Dis       Date:  2014-03-12       Impact factor: 5.996

Review 7.  Amyloidogenesis of Tau protein.

Authors:  Bartosz Nizynski; Wojciech Dzwolak; Krzysztof Nieznanski
Journal:  Protein Sci       Date:  2017-09-13       Impact factor: 6.725

8.  Test and Evaluation of ff99IDPs Force Field for Intrinsically Disordered Proteins.

Authors:  Wei Ye; Dingjue Ji; Wei Wang; Ray Luo; Hai-Feng Chen
Journal:  J Chem Inf Model       Date:  2015-05-13       Impact factor: 4.956

Review 9.  Targeting Abeta and tau in Alzheimer's disease, an early interim report.

Authors:  Todd E Golde; Leonard Petrucelli; Jada Lewis
Journal:  Exp Neurol       Date:  2009-08-27       Impact factor: 5.330

10.  FTDP-17 tau mutations induce distinct effects on aggregation and microtubule interactions.

Authors:  Benjamin Combs; T Chris Gamblin
Journal:  Biochemistry       Date:  2012-10-18       Impact factor: 3.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.